The Josep Carreras Leukaemia Research Institute (IJC) is a comprehensive cancer research center dedicated to conduct research and drive innovation in the epidemiological, preventive, clinical, translational, and basic aspects of leukaemia and other hematologic malignancies, with the final aim of finding a cure for these diseases. It was created in 2010, and since then has experienced an exponential growth.
The IJC is also part of the network of Excellence Research Centers of Catalonia (CERCA) and was accredited as a Severo Ochoa Center of Excellence by the Ministry of Science, Innovation, and Universities in 2024. Since 2018, the Institute has also been accredited by the Scientific Foundation of the Spanish Association Against Cancer (FCAECC) Additionally, IJC is one of the centers integrated into the Institut de Recerca Germans Trias i Pujol (IGTP) accreditation as Accredited Health Research Institute (IIS) by the Carlos III Health Institute (ISCIII).
The IJC's main headquarters is located within the Can Ruti Biomedical Campus, alongside other leading biomedical institutions, providing direct access to cutting-edge scientific and technological facilities, as well as complementary community services. The IJC has six locations integrated into reference hospitals: Hospital Germans Trias i Pujol, Hospital Clínic, Hospital Sant Pau, Hospital Josep Trueta, Hospital del Mar and Hospital San Joan de Déu. This facilitates close collaboration between basic and clinical researchers, fostering translational research that integrates basic science with clinical practice in clinical settings.
The Josep Carreras Leukemia Research Institute is looking for a Junior Group Leader for our Can Ruti Campus.
RESEARCH DESCRIPTION
IJC performs biomedical research and personalized medicine in the field of malignant blood diseases, especially leukaemia. One of the current priorities of the IJC is the understanding of the molecular basis underlaying malignant blood diseases. This basic knowledge is the base for the implementation of new therapeutic strategies to improve patient survival.
This contract is initially funded through grant RYC2019-026415-I, financed by the Spanish Ministry of Science, Innovation and Universities (MICIU) and the State Research Agency (AEI) (10.13039/501100011033), with co-funding from the European Social Fund (ESF) under the initiative "The ESF invests in your future."
WHAT WE NEED
IJC performs biomedical research and personalized medicine in the field of malignant blood diseases, especially leukaemia. One of the current priorities of the IJC is the understanding of the molecular basis underlaying malignant blood diseases. This basic knowledge is the base for the implementation of new therapeutic strategies to improve patient survival.
This contract is initially funded through grant RYC2019-026415-I, financed by the Spanish Ministry of Science, Innovation and Universities (MICIU) and the State Research Agency (AEI) (10.13039/501100011033), with co-funding from the European Social Fund (ESF) under the initiative "The ESF invests in your future."
WHAT WE OFFER
A permanent contract linked to scientific evaluations (contract “Investigador Distinguido”)
Full time contract.
Junior Group Leaders at IJC are provided with suitable laboratory space and access to the state-of-the-art core facilities at IJC.
Be part of a young, collaborative and international work environment with cutting edge technologies and interdisciplinary teams of scientists, including experts in medicine, immunology, genomics and bioinformatics.
Exciting and innovative research projects in the fields of leukaemia, lymphocyte biology and associated malignancies.
The stimulating environment of the Barcelona metropolitan area.
DEADLINE
Please submit your application by August 19, 2026.
WHO WE ARE?
The mission of the Josep Carreras Leukaemia Research Institute is to conduct research and drive innovation in the epidemiological, preventive, clinical, translational, and basic aspects of cancer, with a special emphasis on Leukaemia and other malignant blood diseases, with the aim of finding a cure for these diseases.
The IJC’s vision is to be a world-class reference and excellent research center that contributes to the improvement of results, and the cure of patients affected by leukaemia and other malignant haemopathies, through innovation, sustainability, social responsibility, talent, and professional experience.
In 2019, IJC was honored with the “Human Resources Excellence in Research Award” by the European Commission, recognizing the alignment of our human resources policies with the European Charter for Researchers and Code of Conduct for the Recruitment of Researchers. The Human Resources Strategy for Researchers (HRS4R) guides research centers of excellence in implementing and upholding these standards within their policies, emphasizing training, professional development, and mobility opportunities.
The IJC’s commitment to these values and principles strengthens our internal policies and ensures that our members have the optimal conditions and environment for their professional development.
The Board of Trustees is composed of representatives of the Generalitat de Catalunya (regional government), University of Barcelona, Autonomous University of Barcelona, the City of Badalona and the Jose Carreras International Leukaemia Foundation
The Catalan government provides hard money on an annual basis. The Jose Carreras International Leukaemia Foundation provides start-up funds, project funds as well as financial support for investments.
The JCI has an international scientific advisory board served by prominent researchers from US and Europe.
The IJC has been awarded ERC and other EU grants.
The IJC is an equal-opportunity employer. We evaluate qualified applicants without regard to race, color, religion, sex, national origin, disability, or other legally protected characteristics.
